瑞银发表研报指，从药明生物(02269.HK) 的业务更新中注意到其前景有所改善，但仍然好坏参半。该行表示，对药明生物去年新增151个项目持正面看法，这超出市场预期及公司指引。
瑞银认为，药明生物研发增长韧性强，其可能会继续保持早期研发服务及合作收入的稳健增长，但晚期合同制造(CMO)增长的可见性需要提高。另外，药明生物重申去年营收按年增加5%至10%的目标，并在今年加速增长，但幅度尚未确定。
瑞银将药明生物目标价由11.5元上调至20.3元，维持“中性”评级，目前预计2025财年收入及每股盈利将分别按年增长15%和21%。鉴于美国《生物安全法案》在去年未通过，增长轨迹将较为温和，并等待CMO可见度的改善。(js/da)(港股报价延迟最少十五分钟。沽空资料截至 2025-01-22 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.